Abstract 4801
Background
X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1) is a tumor suppressor that is frequently lost or down-regulated by aberrant promoter hypermethylation in multiple human cancers. To explore XAF1’s candidacy for a suppressor in breast tumorigenesis, we investigated its expression status in tumor cell lines and tissues, effect on ER regulation of cell growth, and the molecular basis for its function.
Methods
XAF1 expression was examined by RT-PCR, immunoblot and bisulfite sequencing. Molecular basis for the XAF1 interplay with ERa and BRCA1 was defined using gene transfection, siRNA-mediated depletion, immunoprecipitation, pull-down assays, ubiquitination assay, immunohistochemistry and animal studies.
Results
XAF1 expression was lost or abnormally diminished by promoter hypermethylation in a substantial fraction of cell lines and primary tumors. XAF1 expression shows an inverse correlation with ERα expression. In ERα-expressing cells, restoration of XAF1 expression extremely increased cellular sensitivity to estrogen-induced, ERα-mediated apoptosis. Likewise, in ERα-nonexpressing cells, recovery of ERα restoration led to the recovery of apoptotic response to estrogen in XAF1-dependent fashion. Intriguingly, XAF1 was found to directly bind to and destabilizes ERα and this interaction is crucial for its apoptosis-promoting activity. Mechanistically, XAF1 has the characteristic of binding with E3 ligase, XAF1 interacts with BRCA1 and subsequently stimulates BRCA1 binding to ERα and BRCA1-mediated K48 polyubiquitination of ERα. Using a series of truncated mutants, we determined the domains of XAF1, ERα, and BRCA1 that are required for the assembly formation. Additionally, XAF1 was characterized to be upregulated by estrogen at the transcription level through the p38, JNK, and NF-kB signaling pathway.
Conclusions
XAF1 is promoted by estrogen and its activation directs the apoptotic switch of estrogen function through the assembly of BRCA1-mediated ERα destruction complex. Our study illuminates the mechanistic consequence of epigenetic inactivation of XAF1 in human breast tumorigenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sung-Gil Chi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract